TL;DR
This study investigates Rosai-Dorfman Disease (RDD) affecting the central nervous system (CNS), a rare condition that often mimics more common brain tumors like meningiomas. The researchers highlight key imaging features that can help distinguish CNS-RDD and emphasize the importance of surgical resection, with chemotherapy and steroids showing promise for managing relapsed or residual cases.
What Problem Does This Paper Address?
Rosai-Dorfman Disease (RDD) is a benign histiocytic proliferative disorder. While typically affecting lymph nodes, it can rarely involve the central nervous system (CNS-RDD). This CNS involvement presents a significant diagnostic challenge due to its atypical clinical and radiological presentation, often leading to misdiagnosis as meningioma. Furthermore, there's a lack of standardized treatment guidelines for CNS-RDD. This paper aims to shed light on the clinical, radiological, and prognostic aspects of CNS-RDD by analyzing a cohort of 12 patients, hoping to improve diagnostic accuracy and inform treatment strategies.
Methods
This was a retrospective study analyzing clinical data, imaging findings (conventional brain MRI with T1-weighted, T2-weighted, and contrast-enhanced T1-weighted sequences), and pathological results from 12 patients diagnosed with CNS-RDD at Xiangya Hospital between January 2012 and June 2022. The researchers focused on summarizing imaging characteristics, evaluating surgical resection extent, and assessing patient outcomes through follow-up. Immunohistochemistry was used to confirm the diagnosis, looking for positive S100 and CD68 expression, and negative CD1a.
Datasets
The study utilized data from 12 patients diagnosed with CNS-RDD at a single institution (Xiangya Hospital). No new benchmarks or publicly available datasets were introduced.
Key Insights and Ideas
- Mimicking Meningioma: CNS-RDD frequently presents as dura-based masses with homogeneous enhancement, making it easily mistaken for meningioma on initial imaging. This highlights the need for a high index of suspicion.
- Subtle Imaging Clues: While challenging, certain MRI features can point towards CNS-RDD. The "lobulation and/or pseudopodium sign" – where the lesion margin is irregular or the meninges extend into the brain – is a significant indicator. Multiple intracranial lesions also raise suspicion.
- Diverse Presentations: CNS-RDD can manifest in various locations, including the cerebral convexity, skull base, brainstem, and even the spinal cord, leading to a wide range of symptoms from headaches and seizures to neurological deficits.
- Surgery as a Primary Treatment: Surgical resection is presented as the primary and effective treatment for CNS-RDD, with total resection offering the best prognosis and a low recurrence rate.
- Adjuvant Therapies for Recurrence: For relapsed or residual CNS-RDD, a combination of chemotherapy (e.g., cytarabine, lenalidomide) and steroid therapy demonstrated promising therapeutic efficacy, leading to complete remission in some cases.
Key Results
- Patient Demographics: The study included 12 patients (9 male, 3 female) with an average age of 41 years (range 12-67).
- Tumor Locations: The most common locations were the cerebral convexity and skull base (9 patients), with two cases of intraparenchymal RDD and one spinal cord lesion.
- Surgical Outcomes: Seven patients underwent total resection, three subtotal resection, one partial resection, and one stereotactic biopsy. Of the seven with total resection, six showed no recurrence during follow-up.
- Treatment Efficacy: One patient with a relapsed lesion and another with residual disease showed complete remission after combination chemotherapy and steroid therapy.
- Prognosis: The mean follow-up time was 50 months. One patient died due to kidney failure and pulmonary infection post-surgery. Another patient experienced disease progression despite steroid therapy.
Limitations and Future Work
The authors acknowledge several limitations:
- Retrospective Design: The study's retrospective nature limits the ability to establish definitive cause-and-effect relationships.
- Small Sample Size: CNS-RDD is rare, resulting in a small cohort (12 patients), which limits the generalizability of the findings.
- Incomplete Systemic Imaging: Some patients did not undergo whole-body imaging, potentially missing latent lesions in other systems.
Future work should focus on prospective studies with larger, multi-center cohorts to further elucidate the pathogenesis, refine diagnostic criteria, and establish standardized treatment protocols for CNS-RDD.
Summary updated